Multiple Sclerosis (MS) is a chronic autoimmune disease that presents with a wide variety of sensory and motor deficiencies. New medications targeting B cells have been approved to treat MS, but the side effect profile has not been widely explored. Herein, we report a case of drug-induced psoriasiform dermatitis following ocrelizumab treatment. Physicians should be cognizant of this possible side effect in patients receiving treatment for MS.
|Original language||English (US)|
|Journal||Dermatology Online Journal|
|State||Published - Jul 1 2018|
- Drug-induced psoriasiform dermatitis
- Multiple sclerosis
- Psoriasiform dermatitis
ASJC Scopus subject areas